Notably, blood tests showed that MAP30 did not impair liver or kidney function in MAP30-treated mice (102)
Published Phase III trials
Hypoglycaemia: Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia
As its name suggests, it provides plenty of nutritional value from protein to iron, and its fortified with B12
Will my GLP-1 medication affect the quality of my plasma
In a press announcement published March 3, 2026 (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making claims that implied sameness with FDA-approved products - specifically calling out companies that advertised drug products in ways that obscured the compounded nature of the product